Gotham Asset Management LLC Boosts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Gotham Asset Management LLC increased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 59.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,690 shares of the medical research company's stock after acquiring an additional 46,313 shares during the quarter. Gotham Asset Management LLC owned about 0.24% of Charles River Laboratories International worth $22,833,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Veracity Capital LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $589,000. Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after purchasing an additional 47,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after buying an additional 1,679 shares during the last quarter. Boston Trust Walden Corp boosted its stake in Charles River Laboratories International by 4.3% in the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after buying an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB raised its stake in shares of Charles River Laboratories International by 225.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after acquiring an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Barclays boosted their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. decreased their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. UBS Group reaffirmed a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average price target of $176.00.

Charles River Laboratories International Trading Down 0.7%

CRL traded down $1.02 during trading on Tuesday, hitting $142.06. 79,183 shares of the stock were exchanged, compared to its average volume of 968,791. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The firm has a 50 day simple moving average of $137.91 and a 200 day simple moving average of $165.93. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of 949.73, a P/E/G ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.27 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).